Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam + Metronidazole in Japanese Patients with cIAI
NCT02739997Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in Intra-abdominal infection (IAI), sponsored by Merck & Co.. Started Apr 2016; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT02739997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739997.